SCHEMBL20480449

SCHEMBL20480449

Clc1ccc2ccc(Br)cc2n1.NC1CCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.51
CYP1A2 P05177 2/20 0.39
HTT P42858 2/20 0.39
CYP2C19 P33261 1/20 0.39
ACHE P22303 6/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
NOS3 P29474 1/20 0.36
NOS1 P29475 1/20 0.36
NOS2 P35228 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20480661 0.97 BACE1 (0.55) BACE1CYP1A2HTTCYP2C19ACHE
Cyclopentanamine SCHEMBL20480640 0.95 BACE1 (0.50) BACE1CYP1A2HTTCYP2C19ACHE
SCHEMBL703102 0.84 BACE1 (0.63) BACE1CYP1A2HTTCYP2C19ACHE
SCHEMBL29471057 0.84 BACE1 (0.63) BACE1CYP1A2HTTCYP2C19ACHE
Tert-Butylamine SCHEMBL20480686 0.78 BACE1 (0.56) BACE1CYP1A2HTTCYP2C19ACHE
Isopropylamine SCHEMBL20480684 0.78 BACE1 (0.56) BACE1CYP1A2HTTCYP2C19ACHE
SCHEMBL22777973 0.71 BACE1 (0.49) BACE1CYP2D6
SCHEMBL789486 0.71 BACE1 (0.64) BACE1CYP1A2HTTCYP2C19MEN1
SCHEMBL29612580 0.69 BACE1 (1.00) BACE1CYP1A2HTTCYP2C19MEN1
SCHEMBL18317038 0.69 BACE1 (1.00) BACE1CYP1A2HTTCYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11883367-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-01-30 US disclosed
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-19 US disclosed
EP-4219496-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP disclosed
US-20230071711-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-03-09 US disclosed
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 US disclosed
EP-3341368-B1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-10-06 EP disclosed
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-11-19 US disclosed
US-10653711-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-05-19 US disclosed
US-20180243328-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 BACE1 1835/4885CYP1A2 3501/4885HTT 3019/4885
US-20230071711-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 BACE1 2184/4885CYP1A2 2522/4885HTT 3861/4885
US-11883367-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 BACE1 2198/4885CYP1A2 2244/4885HTT 3943/4885
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 BACE1 2389/4885CYP1A2 3839/4885HTT 3246/4885
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 BACE1 2092/4885CYP1A2 2128/4885HTT 3966/4885
US-10653711-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 BACE1 1835/4885CYP1A2 3501/4885HTT 3019/4885
US-20180243328-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 BACE1 2184/4885CYP1A2 2522/4885HTT 3861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.